Merck & Co. (MRK) Shares Bought by Hennessy Advisors Inc.

Hennessy Advisors Inc. grew its position in Merck & Co. (NYSE:MRK) by 297.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 154,750 shares of the company’s stock after acquiring an additional 115,800 shares during the quarter. Hennessy Advisors Inc.’s holdings in Merck & Co. were worth $8,429,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of MRK. Cedar Capital LLC raised its stake in shares of Merck & Co. by 25.2% during the fourth quarter. Cedar Capital LLC now owns 4,273 shares of the company’s stock worth $240,000 after purchasing an additional 859 shares during the last quarter. Courier Capital LLC raised its stake in shares of Merck & Co. by 1.1% during the fourth quarter. Courier Capital LLC now owns 82,677 shares of the company’s stock worth $4,652,000 after purchasing an additional 880 shares during the last quarter. San Francisco Sentry Investment Group CA raised its stake in shares of Merck & Co. by 3.6% during the fourth quarter. San Francisco Sentry Investment Group CA now owns 25,156 shares of the company’s stock worth $1,416,000 after purchasing an additional 885 shares during the last quarter. Outfitter Advisors LTD. raised its stake in shares of Merck & Co. by 1.6% during the first quarter. Outfitter Advisors LTD. now owns 55,998 shares of the company’s stock worth $3,050,000 after purchasing an additional 890 shares during the last quarter. Finally, TCI Wealth Advisors Inc. raised its stake in shares of Merck & Co. by 4.9% during the fourth quarter. TCI Wealth Advisors Inc. now owns 19,347 shares of the company’s stock worth $1,089,000 after purchasing an additional 903 shares during the last quarter. 74.87% of the stock is owned by institutional investors and hedge funds.

Merck & Co. opened at $59.14 on Friday, Marketbeat reports. The firm has a market capitalization of $159.26 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 2.25 and a beta of 0.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.42 and a quick ratio of 1.10. Merck & Co. has a 1 year low of $52.83 and a 1 year high of $66.41.

Merck & Co. (NYSE:MRK) last released its quarterly earnings data on Tuesday, May 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.05. The firm had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $10.09 billion. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. Merck & Co.’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.88 earnings per share. sell-side analysts anticipate that Merck & Co. will post 4.23 EPS for the current year.

MRK has been the subject of several analyst reports. BMO Capital Markets restated a “buy” rating on shares of Merck & Co. in a research note on Wednesday, April 25th. Goldman Sachs upgraded Merck & Co. from a “neutral” rating to a “buy” rating and cut their price target for the stock from $60.15 to $58.83 in a research note on Monday, April 23rd. Zacks Investment Research upgraded Merck & Co. from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research note on Tuesday, April 17th. Deutsche Bank restated a “hold” rating on shares of Merck & Co. in a research note on Wednesday, April 25th. Finally, Leerink Swann cut their price target on Merck & Co. from $67.00 to $66.00 and set a “market perform” rating for the company in a research note on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $65.87.

In other Merck & Co. news, insider Weir Mirian M. Graddick sold 24,000 shares of the company’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Julie L. Gerberding sold 9,972 shares of the company’s stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $59.66, for a total value of $594,929.52. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.

Merck & Co. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply